The primary objective of this study is to determine the safety and the immunogenicity of extended treatment with natalizumab when administered at a dose of 300 mg intravenously (IV) to subjects with multiple sclerosis (MS) who have completed natalizumab Studies C-1801, C-1802, or C-1803.
Must give written informed consent. Must be an MS subject who has completed natalizumab Study C-1801, C-1802 or C-1803
Exclusion Criteria:
History of, or available abnormal laboratory results, indicative of any significant disease that would preclude treatment. History of severe allergic or anaphylactic reactions or known drug hypersensitivity A clinically significant infectious illness within 30 days prior to study entry.
Let’s see if you might be eligible for this study.
What is your age and gender ?
Submit
There is 1 Location for this study
See Locations Near You
Performed at only C-1801, C-1802, and C-1803 sites globally. No general public enrollment. Biogen Idec is located in Cambridge Massachusetts, 02142, United States
